VBI VACCINES INC (VBIV) Stock News

USA - Nasdaq - NASDAQ:VBIV - CA91822J2020 - Common Stock

0.0653 USD

-0.07 (-50.87%)

Last: 8/7/2024, 8:00:02 PM

0.045 USD

-0.02 (-31.09%)

After Hours: 8/7/2024, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VBIV Latest News, Press Relases and Analysis

All

Press Releases

8 months ago - By: Stocktwits - Mentions: KMX VBR

CarMax Well Positioned For Growth, Says Wedbush: Retail Sentiment Improves

8 months ago - By: Stocktwits - Mentions: KMX VBR

CarMax Shares Dive On Weak Q4 Print, But Retail Bets Trump Tariffs Will Rev Up Used Car Demand

a year ago - By: InvestorPlace - Mentions: CYRX DZSI EBS EVAV ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

a year ago - By: Benzinga - Mentions: XAIR ZCMD EVO LUMN ...

Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

a year ago - By: Benzinga - Mentions: RGC ELEV JMIA LUMN ...

Dow Jumps Over 300 Points; US Trade Gap Narrows In June

a year ago - By: InvestorPlace

Why Is VBI Vaccines (VBIV) Stock Up 62% Today?

2 years ago - By: BusinessInsider

News Image

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

a year ago - By: InvestorPlace - Mentions: AGRI ATPC CHGG CRVO ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Provides an Update on its Restructuring Proceedings

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

a year ago - By: VBI Vaccines Inc.

VBI Vaccines Announces Results of Annual General Meeting

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

2 years ago - By: InvestorPlace

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Reports First Quarter 2024 Financial Results

2 years ago - By: InvestorPlace

VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Reports Full Year 2023 Financial Results

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2 years ago - By: InvestorPlace - Mentions: MDIA FAAS HUBC GRIN ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform

2 years ago - By: Seeking Alpha

VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences

2 years ago - By: VBI Vaccines Inc.

VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences

2 years ago - By: Brii Biosciences Limited

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Reports Third Quarter 2023 Financial Results

2 years ago - By: VBI Vaccines Inc.

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program